{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:28:37Z","timestamp":1794266917847,"version":"4.9.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib\u2019s effect and identify potential correlated effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration:<\/jats:italic>\n                      The study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-023-02444-z","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:06:12Z","timestamp":1684296372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial"],"prefix":"10.1186","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct03218917","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David","family":"Cipolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Teper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Mange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","volume":"9","author":"HR Keir","year":"2021","unstructured":"Keir HR, Shoemark A, Dicker AJ, et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respir Med. 2021;9:873.","journal-title":"Lancet Respir Med"},{"key":"2444_CR2","first-page":"6","volume":"147","author":"PJ Cole","year":"1986","unstructured":"Cole PJ. Inflammation: a two-edged sword\u2014the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6.","journal-title":"Eur J Respir Dis Suppl"},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392:880.","journal-title":"Lancet"},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1479972317709649","volume":"14","author":"D Weycker","year":"2017","unstructured":"Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of non-cystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017;14:377.","journal-title":"Chron Respir Dis"},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","volume":"195","author":"JD Chalmers","year":"2017","unstructured":"Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med. 2017;195:1384.","journal-title":"Am J Respir Crit Care Med"},{"key":"2444_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/293053","volume":"2015","author":"MS Twigg","year":"2015","unstructured":"Twigg MS, Brockbank S, Lowry P, FitzGerald SP, Taggart C, Weldon S. The role of serine proteases and antiproteases in the cystic fibrosis lung. Mediators Inflamm. 2015;2015: 293053.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"2444_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.biochi.2007.10.009","volume":"90","author":"B Korkmaz","year":"2008","unstructured":"Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie. 2008;90(2):227.","journal-title":"Biochimie"},{"key":"2444_CR8","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.4049\/jimmunol.173.12.7277","volume":"173","author":"CT Pham","year":"2004","unstructured":"Pham CT, Ivanovich JL, Raptis SZ, et al. Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C\/dipeptidyl peptidase I deficiency in humans. J Immunol. 2004;173:7277.","journal-title":"J Immunol"},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1124\/pr.110.002733","volume":"62","author":"B Korkmaz","year":"2010","unstructured":"Korkmaz B, Horwitz MS, Jenne DE, et al. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010;62:726.","journal-title":"Pharmacol Rev"},{"key":"2444_CR10","doi-asserted-by":"publisher","first-page":"12415","DOI":"10.1074\/jbc.RA118.001922","volume":"293","author":"S Seren","year":"2018","unstructured":"Seren S, Rashed Abouzaid M, Eulenberg-Gustavus C, et al. Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis. J Biol Chem. 2018;293:12415.","journal-title":"J Biol Chem"},{"key":"2444_CR11","doi-asserted-by":"publisher","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","volume":"59","author":"K Doyle","year":"2016","unstructured":"Doyle K, L\u00f6nn H, K\u00e4ck H, et al. Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). J Med Chem. 2016;59:9457.","journal-title":"J Med Chem"},{"key":"2444_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/cpt.1053","volume":"104","author":"R Palm\u00e9r","year":"2018","unstructured":"Palm\u00e9r R, M\u00e4enp\u00e4\u00e4 J, Jauhiainen A, et al. Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. Clin Pharmacol Ther. 2018;104:1155.","journal-title":"Clin Pharmacol Ther"},{"key":"2444_CR13","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","volume":"383","author":"JD Chalmers","year":"2020","unstructured":"Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383:2127.","journal-title":"N Engl J Med"},{"key":"2444_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s40262-022-01147-w","volume":"61","author":"JD Chalmers","year":"2022","unstructured":"Chalmers JD, Usansky H, Rubino CM, et al. Pharmacokinetic\/pharmacodynamic evaluation of the dipeptidyl peptidase 1 inhibitor brensocatib for non-cystic fibrosis bronchiectasis. Clin Pharmacokinet. 2022;61:1457.","journal-title":"Clin Pharmacokinet"},{"key":"2444_CR15","doi-asserted-by":"crossref","unstructured":"Basso, Zhang J, Lasala D, et al. An optimized method of extracting and quantifying active neutrophil serine proteases from human whole blood cells. PLoS One. 2022;17:e0272575.","DOI":"10.1371\/journal.pone.0272575"},{"key":"2444_CR16","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1172\/JCI76009","volume":"124","author":"OE S\u00f8rensen","year":"2014","unstructured":"S\u00f8rensen OE, Clemmensen SN, Dahl SL, et al. Papillon-Lef\u00e8vre syndrome patient reveals species-dependent requirements for neutrophil defenses. J Clin Invest. 2014;124:4539.","journal-title":"J Clin Invest"},{"key":"2444_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1172\/JCI0213462","volume":"109","author":"AM Adkison","year":"2002","unstructured":"Adkison AM, Raptis SZ, Kelley DG, Pham CTN. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest. 2002;109:363.","journal-title":"J Clin Invest"},{"key":"2444_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fphar.2018.00341","volume":"9","author":"S Janciauskiene","year":"2018","unstructured":"Janciauskiene S, Wrenger S, Immenschuh S, et al. The multifaceted effects of alpha1-antitrypsin on neutrophil functions. Front Pharmacol. 2018;9:341.","journal-title":"Front Pharmacol"},{"key":"2444_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.chest.2017.03.056","volume":"152","author":"E Polverino","year":"2017","unstructured":"Polverino E, Rosales-Mayor E, Dale GE, et al. The role of neutrophil elastase inhibitors in lung diseases. Chest. 2017;152:249.","journal-title":"Chest"},{"key":"2444_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.rmed.2012.12.009","volume":"107","author":"R Stockley","year":"2013","unstructured":"Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013;107:524.","journal-title":"Respir Med"},{"key":"2444_CR21","doi-asserted-by":"crossref","unstructured":"Miglietta D, Carnini C, Puviani V, et al. Pharmacological characterization of CHF6333, a novel potent inhaled inhibitor of neutrophil elastase. ERS Int Congress 2016.","DOI":"10.1183\/13993003.congress-2016.OA4539"},{"key":"2444_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1172\/JCI6092","volume":"104","author":"EJ Campbell","year":"1999","unstructured":"Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest. 1999;104:337.","journal-title":"J Clin Invest"},{"key":"2444_CR23","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.celrep.2018.02.062","volume":"22","author":"DM Clancy","year":"2018","unstructured":"Clancy DM, Sullivan GP, Moran HBT. Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing. Cell Rep. 2018;22:2937.","journal-title":"Cell Rep"},{"key":"2444_CR24","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1182\/blood.V94.7.2487.419k07_2487_2496","volume":"94","author":"V Witko-Sarsat","year":"1999","unstructured":"Witko-Sarsat V, Cramer EM, Hieblot C, et al. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood. 1999;94:2487.","journal-title":"Blood"},{"issue":"1","key":"2444_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1203\/01.pdr.0000250043.90468.c2","volume":"61","author":"J Sedor","year":"2007","unstructured":"Sedor J, Hogue L, Akers K, et al. Cathepsin-G interferes with clearance of Pseudomonas aeruginosa from mouse lungs. Pediatr Res. 2007;61(1):26.","journal-title":"Pediatr Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02444-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:14:22Z","timestamp":1684296862000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02444-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02444-z","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"28 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The WILLOW trial was performed in accordance with the ethical principles of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. Approvals from independent ethics committees were obtained. Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DC, JS, DL, CF, AT, KGM, JZ, WP and EJS are employees of Insmed Incorporated, Bridgewater, New Jersey. JDC has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Zambon, and Insmed Incorporated; a grant from Gilead; and personal fees from Novartis and Chiesi. BK has received personal fees from Insmed Incorporated.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}